

2018 Black Hills Winter Residents' CE Seminar

February 24, 2018

7:45am – 11:30am MST

*East Auditorium, Rapid City Regional Hospital
Rapid City, SD*

Joint Providers

**South Dakota Society of Health-System Pharmacists
South Dakota State University College of Pharmacy & Allied Health Professions**



The South Dakota State University College of Pharmacy and Allied Health Professions is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The Universal Program Identification Numbers are listed below.

Agenda: *Saturday, February 24, 2018*

7:45-8:00am *Welcome / Registration*

8:00-8:30am **Direct Oral Anticoagulants (DOACs) in Cancer-Associated Thrombosis**

Nick Young, Pharm.D.

(Knowledge-based CPE)

#0063-9999-18-010-L01-P .05 CEUs

#0063-9999-18-010-L01-T .05 CEUs

8:30-9:00am **A Review on New Agents for the Treatment of Hepatitis C**

Margit Hansing, Pharm.D.

(Knowledge-based CPE)

#0063-9999-18-011-L01-P .05 CEUs

#0063-9999-18-011-L01-T .05 CEUs

9:00-9:30am **Controversies in Oral Anticoagulation in Chronic Kidney Disease-Stage 5 Patients with Nonvalvular Atrial Fibrillation**

Ella Pegelow Pharm.D.

(Knowledge-based CPE)

#0063-9999-18-012-L01-P .05 CEUs

#0063-9999-18-012-L01-T .05 CEUs

9:30-9:45am *Break*

9:45-10:15am **Shingles Prevention: Shingrix® vs Zostavax®**

Dacey Eggers, Pharm.D.

(Knowledge-based CPE)

#0063-9999-18-013-L06-P .05 CEUs

#0063-9999-18-013-L06-T .05 CEUs

10:15-10:45am **Bridging the Gaps in Periprocedural Anticoagulation Management for Atrial Fibrillation Patients**

Brittanie Venard, Pharm.D.

(Knowledge-based CPE)

#0063-9999-18-014-L01-P .05 CEUs

#0063-9999-18-014-L01-T .05 CEUs

10:45-11:15am **2018 Diabetes Update**

Amanda Janisch, Pharm.D.

(Knowledge-based CPE)

#0063-9999-18-015-L01-P .05 CEUs

#0063-9999-18-015-L01-T .05 CEUs

11:15-11:30am *Wrap-up / evaluations / CE Credit reconciliation*

It is the policy of the South Dakota State University College of Pharmacy that all continuing education programming present evidence-based information that is non-commercial and professionally objective, not promoting, nor appearing to promote, any specific product or service.

Target Audience: This program is suitable for pharmacists and pharmacy technicians – hospital, community pharmacy and consulting.

C.E. Registration: Please register by clicking the link provided within the e-mail or posted on www.sdshp.com. Preregistration is important, since this will allow for handouts to be sent out in advance of the meeting. If prospective attendees have any problem accessing the registration site from work, they should be able to gain access from their home computer.

C.E. Handouts: Handouts / learning assessment will be available electronically for all participants.

C.E. Credit: Successful completion of each CE session requires continuous attendance, signing the roster, completion of the CPE *Verification Form*, and completion of the *Evaluation/Learning Assessment* form. Credit may be earned for individual sessions. A total of 0.3 CEUs (3.0 contact hours) of continuing pharmacy education credit may be earned at this seminar.

Pharmacists and Technicians must enter their **CPE ID number** and their personal **MM/DD** – on their *Verification Forms* to facilitate the credit award process. Significant delays in providing this information may jeopardize credit award. *Credit uploaded to participant eProfile accounts expected within 14 business days. All participants should subsequently check their NABP accounts to verify appropriate credit upload.*

Faculty Presenters:

Nick Young, Pharm.D., PGY1 Pharmacy Resident, Rapid City Regional Hospital, Rapid City, SD
“Direct Oral Anticoagulants (DOACs) in Cancer-Associated Thrombosis”

Pharmacist learning objective: 1. Review current guideline recommendations for anticoagulation in Cancer-Associated Thrombosis; 2. Evaluate the literature for the use of Direct Oral Anticoagulants (DOACs) in Cancer-Associated Thrombosis.

Technician learning objectives: 1. Identify the generic and brand names of Direct Oral Anticoagulants (DOACs); 2. Identify different formulations of medications available for treatment of VTE.

Margit Hansing, Pharm.D., PGY1 Pharmacy Resident, VA Black Hills Health Care System, Fort Meade, SD
“A Review on New Agents for the Treatment of Hepatitis C”

Pharmacist Learning Objectives: 1. Identify new medication approved for the treatment of chronic hepatitis C; 2. Evaluate the efficacy of VOSEVOI™ and MAVYRET™ in the treatment of chronic hepatitis C; 3. Recognize the most common side effects associated with VOSEVOI™ and MAVYRET™.

Technician Learning Objectives: 1. Identify populations as high-risk for acquiring hepatitis C infection; 2. Distinguish brand/generic names for new agents used to treat chronic hepatitis C; 3. Describe storage, handling, and administration recommendations for medications used to treat hepatitis C.

Elizabeth Pegelow, Pharm.D., PGY1 Resident, Rapid City Regional Hosp, Rapid City, SD
“Controversies in Oral Anticoagulation in Chronic Kidney Disease-Stage 5 Patients with Nonvalvular Atrial Fibrillation”

Pharmacist learning objectives: 1. Summarize increased risk factors for patients with nonvalvular atrial fibrillation and CKD-5; 2. Evaluate pharmacokinetic differences in oral anticoagulants utilized for stroke prevention in CKD-5 with nonvalvular atrial fibrillation; 3. Evaluate the current recommendations for oral anticoagulation in CKD-5 patients with nonvalvular atrial fibrillation.

Pharmacy Technician learning objectives: 1. Identify oral anticoagulants commonly used in stroke prevention for atrial fibrillation patients; 2. Differentiate between the classes of chronic kidney disease; 3. Distinguish between brand and generic names for oral anticoagulant medications.

Dacey R. Eggers, Pharm.D., PGY1 Pharmacy Resident, VA Black Hills Health Care System, Fort Meade, SD
“Shingles Prevention: Shingrix® vs Zostavax®”

Pharmacist learning objectives: 1. Explain the pathophysiology of Herpes Zoster and its relation to chickenpox and shingles; 2. Evaluate treatments for shingles prevention and areas where Shingrix® (Zoster Vaccine - Recombinant, Adjuvanted) may have better efficacy than Zostavax® (Zoster Vaccine Live).

Pharmacy Technician learning objectives: 1. Describe key symptoms of Shingles; 2. Explain when Shingrix® can be administered to patients.

Brittanie Venard, Pharm.D. PGY1 Pharmacy Resident, Rapid City Regional Hospital, Rapid City, SD
“Bridging the Gaps in Periprocedural Anticoagulation Management for Atrial Fibrillation Patients”

Pharmacist learning objectives: 1. Identify pertinent factors that should be considered when developing a periprocedural anticoagulation plan; 2. Given a patient case, design an appropriate periprocedural anti-coagulation plan for a patient with nonvalvular atrial fibrillation on chronic anticoagulation.

Technician learning objectives / Learning assessment questions:

1. Define the role of chronic anticoagulation in atrial fibrillation patients; 2. Identify brand and generic names of direct oral anticoagulants.

Amanda Janisch, Pharm.D., PGY1 Pharmacy Resident, VA Black Hills Health Care System, Fort. Meade, SD
“2018 Diabetes Update”

Pharmacist Learning Objectives: 1. List diabetes medications that have shown a reduction in cardiovascular events; 2. Describe patient specific factors that guide therapy selection; 3. Identify guideline recommended lipid lowering agents and goals of therapy.

Technician Learning Objectives: 1. Categorize diabetes medications based on cost; 2. Describe diabetes specific vaccination requirements for adults.

Guidance and oversight on CPE development for each presentation was provided by the following Residency Directors / mentors:

Amy Doten, Pharm.D., Black Hills VA Health Care System, Fort Meade, SD

Katie Hayes, Pharm.D., Rapid City Regional Hospital, Rapid City, SD